Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En undersøgelse af nye anti-cancermidler hos patienter med metastatisk tredobbelt negativ brystkræft (BEGONIA)

9. november 2026 opdateret af: AstraZeneca

Et fase IB/II, 2-trins, åbent, multicenter-studie for at bestemme effektiviteten og sikkerheden af ​​Durvalumab (MEDI4736) + Paclitaxel og Durvalumab (MEDI4736) i kombination med nye onkologiske terapier med eller uden paclitaxel til førstelinjemetastatisk triple Negativ brystkræft

This study is designed to determine the efficacy and safety of durvalumab in combination with novel oncology therapies with or without paclitaxel and durvalumab + paclitaxel for first-line metastatic triple negative breast cancer

Studieoversigt

Status

Aktiv, ikke rekrutterende

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

This is a Phase IB/II, 2-stage, open-label, multicenter study to determine the efficacy and safety of durvalumab in combination with novel oncology therapies (i.e. therapies designed for immune modulation) with or without paclitaxel and durvalumab + paclitaxel as first-line treatment in patients with metastatic triple negative breast cancer (TNBC). The study is designed to concurrently evaluate potential novel treatment combinations with clinical promise using a 2-stage approach. The study will use a Simon 2-Stage design to evaluate which cohorts may proceed to expansion.

Part 1 is a Phase IB study of safety and initial efficacy, and Part 2 may expand patient enrollment if adequate efficacy signal is observed in Part 1. The treatment regimens evaluated in Part 2 will depend on the evaluation of safety and efficacy outcomes in Part 1.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

243

Fase

  • Fase 2
  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • British Columbia
      • Kelowna, British Columbia, Canada, V1Y 5L3
        • Research Site
    • Ontario
      • London, Ontario, Canada, N6A 4L6
        • Research Site
    • Quebec
      • Greenfield Park, Quebec, Canada, J4V 2H1
        • Research Site
      • Montreal, Quebec, Canada, H4A 3J1
        • Research Site
      • Cambridge, Det Forenede Kongerige, CB2 0QQ
        • Research Site
      • London, Det Forenede Kongerige, EC1M 6BQ
        • Research Site
      • Manchester, Det Forenede Kongerige, M20 4BX
        • Research Site
      • Oxford, Det Forenede Kongerige, OX3 7LE
        • Research Site
    • Arizona
      • Tucson, Arizona, Forenede Stater, 85715
        • Research Site
    • Maryland
      • Columbia, Maryland, Forenede Stater, 21044
        • Research Site
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02114
        • Research Site
      • Boston, Massachusetts, Forenede Stater, 02215
        • Research Site
    • Michigan
      • Grand Rapids, Michigan, Forenede Stater, 49503
        • Research Site
    • Missouri
      • St Louis, Missouri, Forenede Stater, 63110
        • Research Site
    • Texas
      • Dallas, Texas, Forenede Stater, 75246
        • Research Site
    • Virginia
      • Williamsburg, Virginia, Forenede Stater, 23188
        • Research Site
      • Gdansk, Polen, 80-952
        • Research Site
      • Krakow, Polen, 31-501
        • Research Site
      • Lublin, Polen, 20-090
        • Research Site
      • Opole, Polen, 45-060
        • Research Site
      • Rzeszów, Polen, 35-021
        • Research Site
      • Warsaw, Polen, 02-781
        • Research Site
      • Warsaw, Polen, 04-141
        • Research Site
      • Seoul, Sydkorea, 03080
        • Research Site
      • Seoul, Sydkorea, 05505
        • Research Site
      • Seoul, Sydkorea, 06351
        • Research Site
      • Kaohsiung City, Taiwan, 80756
        • Research Site
      • Taichung, Taiwan, 40447
        • Research Site
      • Tainan, Taiwan, 70403
        • Research Site
      • Taipei, Taiwan, 10002
        • Research Site
      • Taipei, Taiwan, 112
        • Research Site
      • Taoyuan, Taiwan, 333
        • Research Site

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 130 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Kvinde

Beskrivelse

Inclusion criteria

  1. Female
  2. At least 18 years of age at the time of screening
  3. Patient must have locally confirmed advanced/unresectable or metastatic TNBC.
  4. No prior treatment for metastatic (Stage IV) TNBC
  5. Patient must have at least 1 lesion, not previously irradiated, that can be accurately measured
  6. WHO/ECOG status at 0 or 1 at enrollment

Patients enrolled to Arm 6 (durvalumab and DS-8201a) Must provide documentation of locally determined advanced/unresectable or metastatic TNBC with HER2 low tumor expression (IHC 2+/ISH-, IHC 1+/ISH-, or IHC 1+/ISH untested)

Patients enrolled in Arm 8 (durvalumab + Dato-DXd) Must have PD-L1 positive tumor as determined by an IHC based assay

Exclusion criteria

  1. History of allogeneic organ transplantation
  2. Active or prior documented autoimmune or inflammatory disorders
  3. Active infection including tuberculosis, hepatitis B (known positive HBV surface antigen [HBsAg] result), hepatitis C virus (HCV), or human immunodeficiency virus (positive HIV 1/2 antibodies)
  4. Untreated CNS metastases
  5. Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients
  6. Any concurrent chemotherapy, IP, or biologic therapy for cancer treatment
  7. Female patients who are pregnant, breastfeeding
  8. Cardiac Ejection Fraction less than 50%

Patients enrolled in Arm 2 only:

  1. Potent inhibitors or inducers or substrates of CYP3A4 or substrates of CYP2C9 or CYP2D6 within 2 weeks before the first dose of study treatment (3 weeks for St John's Wort)
  2. Diagnosis of diabetes mellitus Type I or diabetes mellitus Type II requiring insulin treatment.
  3. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events, such as heart failure, hypokalemia, potential for torsades de pointes, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age, or any concomitant medication known to prolong the QT interval
  4. Prior treatment with PI3K inhibitors, AKT inhibitors, or mammalian target of rapamycin (mTOR) inhibitors.

Patients enrolled in Arm 5 only: History of venous thromboembolism in the past 3 months

Patients enrolled in Arm 7 and 8 only: Clinically significant corneal disease in the opinion of the Investigator.

Patients enrolled in Arm 6, 7 and 8 only:

  1. History of or active interstitial lung disease/pneumonitis
  2. Use of chloroquine or hydroxychloroquine in <14 days prior to Day 1 of DS-8201a (Arm 6) or Dato-DXd (DS-1062a; Arm 7 and 8) treatment
  3. Patients enrolled in Arm 6 only: Previously been diagnosed as HER2+ or received HER2-targeted therapy.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Arm 1

durvalumab + paclitaxel

Durvalumab iv Every 4 weeks (q4w) or 3 weeks (q3w) Arm 6, 7 and 8

Andre navne:
  • MEDI4736

Paclitaxel iv 4-week cycles: 3 weeks once weekly (q1w) and 1 week off

Eksperimentel: Arm 2

durvalumab + paclitaxel + capivasertib

Durvalumab iv Every 4 weeks (q4w) or 3 weeks (q3w) Arm 6, 7 and 8

Andre navne:
  • MEDI4736

Paclitaxel iv 4-week cycles: 3 weeks once weekly (q1w) and 1 week off

Capivasertib oral bid 4-week cycles; 3 weeks on (dosing on days 2,3,4 and 5) and 1 week off

Andre navne:
  • AZD5363
Eksperimentel: Arm 5

durvalumab + paclitaxel + oleclumab

Durvalumab iv Every 4 weeks (q4w) or 3 weeks (q3w) Arm 6, 7 and 8

Andre navne:
  • MEDI4736

Paclitaxel iv 4-week cycles: 3 weeks once weekly (q1w) and 1 week off

Oleclumab iv Every 2 weeks (q2w) for first 2 cycles (days 1 and 15 in cycles 1 and 2), then every 4 weeks (q4w) starting at cycle 3 day 1

Andre navne:
  • MEDI9447
Eksperimentel: Arm 6

durvalumab + trastuzumab deruxtecan

Durvalumab iv Every 4 weeks (q4w) or 3 weeks (q3w) Arm 6, 7 and 8

Andre navne:
  • MEDI4736

Trastuzumab deruxtecan iv 3-week cycles (once weekly) q3w

Andre navne:
  • DS-8201a
Eksperimentel: Arm 7

durvalumab + datopotamab deruxtecan

Durvalumab iv Every 4 weeks (q4w) or 3 weeks (q3w) Arm 6, 7 and 8

Andre navne:
  • MEDI4736

Datopotamab deruxtecan iv 3-week cycles (once weekly) q3w

Andre navne:
  • Dato-DXd; DS-1062a
Eksperimentel: Arm 8

durvalumab + datopotomab deruxtecan (patients with PD-L1 positive status)

Durvalumab iv Every 4 weeks (q4w) or 3 weeks (q3w) Arm 6, 7 and 8

Andre navne:
  • MEDI4736

Datopotamab deruxtecan iv 3-week cycles (once weekly) q3w

Andre navne:
  • Dato-DXd; DS-1062a

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Dose Limiting Toxicity (DLT) Events
Tidsramme: From the time of first dose until completion of the first cycle (28 days for Arms 2-5, 21 days for Arms 6-7 (no safety run-in for Arms 1 and 8))

The occurrence of a severe adverse event (meeting pre-specified criteria) that is at least possibly related to durvalumab and/or the novel oncology therapy in 6 DLT-evaluable patients

From the time of first dose until completion of the first cycle (28 days for Arms 2-5, 21 days for Arms 6-7 (no safety run-in for Arms 1 and 8))

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Objective Response Rate (ORR)
Tidsramme: Tumor assessments: every 8 wks (Arms 1-5) or every 6 wks (Arms 6-8) until wk 48, then every 12 wks from first IP dose until radiologic progression, death, withdrawal of consent, or study completion; up to max 54 mos (observed longest duration in Arm 1)

Percentage of evaluable patients with a confirmed Investigator-assessed response of CR (complete response) or PR (partial response). Confirmed response is defined as at least one visit response of CR or PR confirmed by a follow-up scan at least 4 weeks later showing CR or PR.

Tumor assessments: every 8 wks (Arms 1-5) or every 6 wks (Arms 6-8) until wk 48, then every 12 wks from first IP dose until radiologic progression, death, withdrawal of consent, or study completion; up to max 54 mos (observed longest duration in Arm 1)
Progression-free Survival (PFS)
Tidsramme: Tumor assessments: every 8 wks (Arms 1-5) or every 6 wks (Arms 6-8) until wk 48, then every 12 wks from first IP dose until radiologic progression, death, withdrawal of consent, or study completion; up to max 54 mos (observed longest duration in Arm 1)

Time from date of first dose (at least one study intervention [durvalumab, paclitxel or novel oncology therapy]) until the date of objective radiological disease progression using RECIST 1.1 or death (by any cause in the absence of progression)

Tumor assessments: every 8 wks (Arms 1-5) or every 6 wks (Arms 6-8) until wk 48, then every 12 wks from first IP dose until radiologic progression, death, withdrawal of consent, or study completion; up to max 54 mos (observed longest duration in Arm 1)
Duration of Response (DoR)
Tidsramme: Tumor assessments: every 8 wks (Arms 1-5) or every 6 wks (Arms 6-8) until wk 48, then every 12 wks from first IP dose until radiologic progression, death, withdrawal of consent, or study completion; up to max 54 mos (observed longest duration in Arm 1)

Time from the date of first documented response (which is subsequently confirmed) until the first date of documented progression (PD) or death in the absence of PD (ie, date of PFS event or censoring - date of first response + 1). If a patient does not progress following a response, then their DoR will be censored at the last evaluable disease assessment date

Tumor assessments: every 8 wks (Arms 1-5) or every 6 wks (Arms 6-8) until wk 48, then every 12 wks from first IP dose until radiologic progression, death, withdrawal of consent, or study completion; up to max 54 mos (observed longest duration in Arm 1)
Overall Survival (Count)
Tidsramme: From date of first dose until date of death due to any cause; up to the maximum of 54 months (observed longest duration in Arm 1)

Number of patients with overall survival, the time from date of first dose (at least one study intervention [durvalumab, paclitxel or novel oncology therapy]) until the date of death by any cause

From date of first dose until date of death due to any cause; up to the maximum of 54 months (observed longest duration in Arm 1)
Overall Survival (Duration)
Tidsramme: From date of first dose of IP until date of death due to any cause; up to the maximum of 54 months (observed longest duration in Arm 1)

Time from date of first dose (at least one study intervention [durvalumab, paclitxel or novel oncology therapy]) until the date of death by any cause

From date of first dose of IP until date of death due to any cause; up to the maximum of 54 months (observed longest duration in Arm 1)
Progression-free Survival at 6 Months (PFS6)
Tidsramme: 6 months following date of first dose

Percentage of patients alive and progression-free at 6 months following date of first dose (at least one study intervention [durvalumab, paclitxel or novel oncology therapy])

6 months following date of first dose

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Ledende efterforsker: Peter Schmid, MD, PhD, Barts Cancer Institute

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

21. december 2018

Primær færdiggørelse (Faktiske)

29. november 2024

Studieafslutning (Anslået)

26. februar 2027

Datoer for studieregistrering

Først indsendt

25. oktober 2018

Først indsendt, der opfyldte QC-kriterier

14. november 2018

Først opslået (Faktiske)

15. november 2018

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

12. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

9. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • D933LC00001
  • 2018 (U.S. NIH-bevilling/kontrakt)
  • 2018-000764-29 (EudraCT nummer)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

IPD-delingstidsramme

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

IPD-delingsadgangskriterier

When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL
  • SAP

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .